Synthesis and antimicrobial screening of tetra Schiff bases of 1,2,4,5-tetra (5-amino-1,3,4-thiadiazole-2-yl)benzene  by Yousif, Emad et al.
Journal of Saudi Chemical Society (2014) 18, 269–275King Saud University
Journal of Saudi Chemical Society
www.ksu.edu.sa
www.sciencedirect.comORIGINAL ARTICLESynthesis and antimicrobial screening of tetra
Schiﬀ bases of 1,2,4,5-tetra (5-amino-
1,3,4-thiadiazole-2-yl)benzene* Corresponding authors. Tel.: +964 7901782816.
E-mail address: emad_yousif@hotmail.com (E. Yousif).
1319-6103 ª 2011 King Saud University. Production and hosting by
Elsevier B.V.
Peer review under responsibility of King Saud University.
doi:10.1016/j.jscs.2011.07.007
Production and hosting by Elsevier
Open access under CC BY-NC-N
Open access under CC BY-NC-ND license.Emad Yousif a,*, Eva Rentschler b, Nadia Salih c, Jumat Salimon c, Ayad Hameed a,
Mustafa Katan aa Department of Chemistry, College of Science, Al-Nahrain University, Baghdad, Iraq
b Institute of Inorganic and Analytical Chemistry, Johannes Gutenberg University of Mainz, Duesbergweg 10-14, D-55128
Mainz, Germany
c School of Chemical Sciences and Food Technology, Faculty of Science and Technology, Universiti Kebangsaan, Malaysia, 43600
Bangi, Selangor, MalaysiaReceived 12 May 2011; accepted 6 July 2011
Available online 20 July 2011KEYWORDS
Tetra Schiff base;
1,3,4-Thiadiazole;
Antibacterial;
AntifungalAbstract In the present study, novel tetra Schiff bases were synthesized by condensation of 1,2,4,5-
tetra (5-amino-1,3,4-thiadiazole-2-yl)benzene with different aromatic aldehydes. The chemical struc-
tures were conﬁrmed by means of IR, 1H NMR, 13C NMR, and elemental analysis. All compounds
were screened for antibacterial (Staphylococcus aureus ATCC-9144, Staphylococcus epidermidis
ATCC-155, Micrococcus luteus ATCC-4698, Bacillus cereus ATCC-11778, Escherichia coli ATCC-
25922, and Pseudomonas aeruginosa ATCC-2853) and antifungal (Aspergillus niger ATCC-9029
and Aspergillus fumigatus ATCC-46645) activities by paper disc diffusion technique. The minimum
inhibitory concentrations (MICs) of the compounds were also determined by agar streak dilution
method. Among the synthesized compounds 1,2,4,5-tetra[5-(4-nitrobenzylideneamino)-1,3,4-thiadia-
zole-2-yl]benzene 7 was found to be the most potent antimicrobial activity with MICs of 3.4, 2.1, 1.2,
2.0, 3.1, 2.4, 1.1, and 1.7 lg/mL against the above mentioned respective strains.
ª 2011 King Saud University. Production and hosting by Elsevier B.V.D license.1. Introduction
Schiff bases represent an important class of organic com-
pounds, especially in the medicinal and pharmaceutical ﬁelds.
Thus, development and synthesis of novel Schiff base deriva-
tives as potential chemotherapeutics still attract the attention
of organic and medicinal chemist (Bharti et al., 2010; da Silva
et al., 2011; Rosu et al., 2011). Many studies reported the bio-
logical activities of Schiff bases, including their anticancer,
antibacterial, antifungal, and herbicidal activities (Gudipati
270 E. Yousif et al.et al., 2011). Schiff bases, derived mostly from variety of het-
erocyclic rings, were reported to possess a broad spectrum
and a wide variety of biological activities including antiviral,
anticancer, cytotoxic, antimicrobial, antibacterial, anticonvul-
sant, etc. (Hranjec et al., 2011). A number of Schiff bases have
been tested for antibacterial, antifungal, anticancer and herbi-
cidal activities (Prasad et al., 2011; Pulate et al., 2011).
The treatment of infectious diseases still remains an impor-
tant and challenging problem because of a combination of fac-
tors including emerging infectious diseases and increasing
number of multi-drug resistant microbial pathogens with par-
ticular relevance for Gram-positive bacteria. In spite of the
large number of antibiotics and chemotherapeutics available
for medical use, the emergence of old and new antibiotic resis-
tant bacterial strains in the last decades constitutes a substan-
tial need for the new class of antibacterial agents.
The varied biological activities of 1,3,4-thiadiaziles and
their analogs have been known from the beginning of the
20th century (Bhat et al., 2011; Gilani et al., 2010). Literature
survey revealed that slight modiﬁcation in the structure can re-
sult in qualitative as well as quantitative changes in the activity
(Alagawadi and Alegaon, 2010; Dong et al., 2010; Bhat et al.,
2011). This prompted us to undertake the synthesis of various
novel tetra Schiff bases derived from 1,2,4,5-tetra (5-amino-
1,3,4-thiadiazole-2-yl)benzene and characterized using IR, 1H
NMR, 13C NMR, and Elemental analysis with the aim of hav-
ing improved activity. The synthesized compounds were
screened for their antibacterial activity against four Gram-po-
sitive bacteria (Staphylococcus aureus ATCC-9144, Staphylo-
coccus epidermidis ATCC-155, Micrococcus luteus ATCC-
4698 and Bacillus cereus ATCC-11778), three Gram-negative
bacteria (Escherichia coli ATCC-25922, Pseudomonas aerugin-
osa ATCC-2853 and antifungal (Aspergillus niger ATCC-9029
and Aspergillus fumigatus ATCC 46645) activities by paper
disc diffusion technique. The minimum inhibitory concentra-
tions (MICs) of the compounds were also determined by agar
streak dilution method.
2. Experimental
2.1. Measurements
The melting points were taken in an open capillary tube and
are uncorrected. The IR spectra of the compounds were re-
corded on ABB Bomem FT-IR spectrometer MB 104 with
KBr pellets. 1H and 13C NMR spectra were recorded using a
Bruker 300 NMR spectrometer operating at 400.13 and
100.77 MHz, respectively. Microanalyses were obtained with
an Elemental analyses system GmbH VarioEL V300 element
analyzer. The purity of the compounds was checked by TLC
on pre-coated SiO2 gel (HF254, 200 mesh) aluminium plates
(E Merk) and visualized in UV chamber. IR, 1H NMR, 13C
NMR and elemental analysis were consistent with the assigned
structures.
2.2. Synthesis
2.2.1. Synthesis of 1,2,4,5-tetra (5-amino-1,3,4-thiadiazole-2-
yl)benzene 2
A mixture of pyromellitic acid 1 (0.01 mol, 2.54 g) and
(0.04 mol, 3.64 g) of thiosemicarbazide with (15 mL) of phos-phorusoxy chloride was reﬂuxed gently for 15 h, the comple-
tion of the reaction mixture monitored by TLC. After
cooling, 125 mL of water was added, the mixture was then re-
ﬂuxed for 10 h, ﬁltrated, and neutralized with potassium
hydroxide. The precipitate was washed with water and recrys-
tallized from (ethanol-water) to give the desired product.
(Yield 80%). mp > 360 C; IR (KBr) cm1: 3325–3298 (m
NH2), 3081 (mC–H), 1610 (mC‚N), 1534 (mC‚C).
1H NMR
(DMF-d6) d ppm 8.87 (s, 2H, NH2) (D2O exchange, disap-
peared), 8.76 (s, 2H, NH2) (D2O exchange, disappeared),
8.70 (s, 2H, NH2) (D2O exchange, disappeared), 8.62 (s, 2H,
NH2) (D2O exchange, disappeared), 7.50 (s, 1H, ar-H), 7.44
(s, 1H, ar-H). 13C NMR (DMF-d6) d ppm 143.22–148.31
(6C, ar-C), 137.11–140.40 (8C, thiadiazole carbons). Anal.
Found (calc.) for C14H10N12S4 (%): C, 35.44 (35.43); H, 2.13
(2.12); N, 35.41 (35.42), S, 27.04 (27.03).
2.2.2. General method of synthesis 3–10
A mixture of 1,2,4,5-tetra (5-amino-1,3,4-thiadiazole-2-yl)ben-
zene (0.01 mol) and appropriate aromatic aldehyde (0.04 mol)
was dissolved in 35 mL of absolute ethanol. The mixture was
then reﬂuxed for 20–24 h with stirring, the completion of the
reaction mixture monitored by TLC. After cooling to room
temperature, a solid was obtained. The crude product was ﬁl-
tered, dried and recrystallized from ethanol.
2.2.2.1. 1,2,4,5-Tetra[5-benzylideneamino-1,3,4-thiadiazole-2-
yl]benzene 3. (Yield: 87%). mp 220–221 C; IR (KBr) cm1:
3100 (m C–H), 1612 (m C=N), 1560 (m C=C).
1H NMR (DMF-
d6) d ppm 8.02–8.05 (d, 1H, ar-H), 7.95–8.01 (d, 1H, ar–H),
7.63–7.67 (d, 1H, ar–H), 7.57–7.60 (d, 1H, ar–H), 7.51–7.54
(d, 1H, ar–H), 7.50 (s, 1H, ar–H), 7.44–7.47 (d, 1H, ar–H),
7.40 (s, 1H, ar–H), 7.29–7.33 (d, 1H, ar–H), 7.19–7.22 (m,
3H, ar–H), 7.11–7.14 (m, 3H, ar–H), 7.00–7.03 (m, 3H, ar–
H), 6.83–6.86 (m, 4H, ar–H), 5.74 (s, 1H, –CH=N–), 5.70
(s, 1H, –CH=N–), 5.63 (s, 1H, –CH=N–), 5.58 (s, 1H, –
CH=N–). 13C NMR (DMF-d6) d ppm 138.15–147.13 (12C,
ar–C), 132.43–137.34 (12C, ar–C), 130.56–134.78 (6C, ar–C),
125.02–129.15 (8C, thiadiazole carbons), 115.31–119.40 (4C,
–C=N–). Anal. Found (calc.) for C42H26N12S4 (%): C, 61.01
(61.00); H, 3.18 (3.17); N, 20.33 (20.32), S, 15.50 (15.51).
2.2.2.2. 1,2,4,5-Tetra[5-(4-methylbenzylideneamino)-1,3,4-
thiadiazole-2-yl]benzene 4. (Yield: 73%). mp 200–201 C; IR
(KBr) cm1 3090 (m C–H), 1615 (m C=N), 1560 (m C=C).
1H
NMR (DMF–d6) d ppm 8.08–8.10 (d, 1H, ar–H), 7.97–8.00
(d, 1H, ar–H), 7.84–7.87 (d, 1H, ar–H), 7.61–7.65 (d, 1H,
ar–H), 7.51 (s, 1H, ar–H), 7.53–7.55 (d, 1H, ar–H), 7.45–7.47
(d, 1H, ar–H), 7.43 (s, 1H, ar–H), 7.28–7.31 (m, 2H, ar–H),
7.21–7.25 (m, 2H, ar–H), 7.18–7.20 (m, 2H, ar–H), 6.02–7.07
(m, 2H, ar–H), 6.77–6.80 (m, 2H, ar–H), 5.79 (s, 1H,
–CH=N–), 5.73 (s, 1H, –CH=N–), 5.66 (s, 1H, –CH=N–),
5.60 (s, 1H, –CH=N–). 13C NMR (DMF–d6) d ppm 140.12–
145.78 (12C, ar–C), 134.12–136.46 (12C, ar–C), 130.20–
134.13 (6C, ar–C), 125.26–130.24 (8C, thiadiazole carbons).
Anal. Found (calc.) for C46H34N12S4 (%): C, 62.57 (62.56);
H, 3.87 (3.88); N, 19.04 (19.03), S, 14.51 (14.52).
2.2.2.3. 1,2,4,5-Tetra[5-(4-hydroxybenzylideneamino)-1,3,4-
thiadiazole-2-yl]benzene 5. (Yield: 80%). mp > 360 C; IR
(KBr) cm1 3435 (m O–H), 3095 (m C–H), 1613 (m C=N), 1560
Table 1 Effect of synthesized compounds on human pathogenic tested microorganisms.
Compounds In vitro activity-zone of inhibition in mm (MIC in lg/mL)
S. aureus,
ATCC-9144
S. epidermidis,
ATCC-155
M. luteus,
ATCC-4698
B. cereus,
ATCC-11778
E. coli,
ATCC-25922
P. aeruginosa,
ATCC-2853
A. niger,
ATCC-9092
A. fumigatus,
ATCC-46645
1 5 3 4 1 2 3 6 4
(1.4) (2.6) (5.1) (2.3) (1.5) (2.4) (3.9) (2.3)
2 19 20 18 19 19 16 20 23
(27.9) (22.2) (10.1) (31.9) (29.9) (36.2) (33.4) (10.1)
3 24 22 26 21 23 25 27 24
(17.3) (20.9) (17.2) (19.3) (21.8) (22.6) (19.0) (9.1)
4 21 19 20 23 19 27 26 25
(10.7) (28.4) (25.6) (21.6) (24.2) (20.2) (22.8) (21.8)
5 25 22 22 23 20 23 21 20
(10.2) (12.6) (22.4) (27.4) (32.8) (30.2) (34.2) (31.2)
6 24 25 26 25 24 23 27 24
(14.4) (10.9) (18.9) (19.1) (18.8) (21.7) (18.2) (19.3)
7 28 26 24 23 23 24 17 24
(3.4) (2.1) (1.2) (2.0) (3.1) (2.4) (1.1) (1.7)
8 19 23 24 23 20 24 21 23
(16.7) (28.2) (12.7) (15.2) (23.8) (21.4) (22.8) (21.9)
9 25 19 25 24 22 17 18 19
(20.1) (25.1) (19.8) (11.8) (14.6) (28.1) (33.6) (31.8)
10 20 17 19 21 24 22 19 20
(29.4) (8.6) (28.7) (27.7) (9.7) (11.1) (32.1) (22.2)
Ciproﬂoxacin
(100 lg/disc)
29 31 30 29 32 3 33 –
(0.2) (0.39) (0.1) (0.3) (0.2) (0.25) (0.1)
Ketoconazole
(100 lg/disc)
– – – – – – 30 29
(6.1) (0.23)
Dimethylformamide
–
–
–
–
–
–
–
–
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Scheme 1 Reagents and conditions: (i) thiosemicarbazide, POCl3, reﬂux 15 h; (ii) appropriate aromatic aldehyde, absolute ethanol,
reﬂux 10–24 h.
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1H NMR (DMF–d6) d ppm 9.14 (s, 2H, 2OH) (D2O
exchange, disappeared), 9.23 (s, 2H, 2OH) (D2O exchange, dis-
appeared), 8.09–8.13 (d, 1H, ar–H), 7.93–8.03 (d, 1H, ar–H),
7.64–7.70 (d, 1H, ar–H), 7.56–7.58 (d, 1H, ar–H), 7.53 (1H,
s, ar–H), 7.46–7.48 (d, 1H, ar–H), 7.43 (1H, s, ar–H), 7.35–
7.38 (d, 1H, ar–H), 7.31–7.33 (d, 1H, ar–H), 7.25–7.27 (m,
3H, ar–H), 7.17–7.20 (m, 3H, ar–H), 7.13–7.14 (m, 3H, ar–H), 5.76 (s, 1H, –CH=N–), 5.70 (s, 1H, –CH=N–), 5.63 (s,
1H, –CH=N–), 5.58 (s, 1H, –CH=N–). 13C NMR (DMF–
d6) d ppm 143.05–147.14 (12C, ar–C), 138.10–141.72 (12C,
ar–C), 133.89–136.67 (6C, ar–C), 126.90–129.65 (8C, thiadia-
zole carbons). Anal. Found (calc.) for C42H26N12O4S4 (%):
C, 56.61 (56.62); H, 2.95 (2.94); N, 18.87 (18.86), S, 14.41
(14.40).
Figure 1 Illustration of how some antimicrobial agents are
rendered ineffective (Fluit et al., 2001).
Synthesis and antimicrobial screening of tetra Schiff bases of 1,2,4,5-tetra (5-amino- 1,3,4-thiadiazole-2-yl)benzene 2732.2.2.4. 1,2,4,5-Tetra[5-(2-hydroxybenzylideneamino)-1,3,4-
thiadiazole-2-yl]benzene 6. (Yield: 59%). mp > 360 C; IR
(KBr) cm1 3423 (m O–H), 3010 (m C–H), 1617 (m C=N), 1543 (m
C=C).
1H NMR (DMF–d6) d ppm 9.20 (s, 2H, 2OH) (D2O ex-
change, disappeared), 9.27 (s, 2H, 2OH) (D2O exchange, dis-
appeared), 8.13–8.16 (d, 1H, ar–H), 8.06–8.09 (d, 1H, ar–H),
7.91–7.94 (d, 1H, ar–H), 7.81–7.83 (d, 1H, ar–H), 7.75–7.78
(d, 1H, ar–H), 7.69–7.71 (d, 1H, ar–H), 7.61–7.63 (d, 1H,
ar–H), 7.54–7.57 (m, 3H, ar–H), 7.51 (1H, s, ar–H), 7.47–
7.50 (m, 3H, ar–H), 7.45 (1H, s, ar–H), 6.40–7.43 (m, 3H,
ar–H), 5.75 (s, 1H, –CH=N–), 5.72 (s, 1H, –CH=N–), 5.61
(s, 1H, –CH=N–), 5.56 (s, 1H, ––CH=N–). 13C NMR
(DMF–d6) d ppm 145.15–147.04 (12C, ar–C), 140.12–143.92
(12C, ar–C), 134.56–138.17 (6C, ar–C), 127.80–130.19 (8C,
thiadiazole carbons). Anal. Found (calc.) for C42H26N12O4S4
(%): C, 56.61 (56.62); H, 2.95 (2.94); N, 18.87 (18.86), S,
14.39 (14.40).
2.2.2.5. 1,2,4,5-Tetra[5-(4-nitrobenzylidene)-1,3,4-thiadiazole-
2-yl]benzene 7. (Yield: 78%). mp 235–236 C; IR (KBr) cm1
3076 (m C–H), 1614 (m C=N), 1543 (m C=C), 1512, 1356 (m N–O).
1H NMR (DMF–d6) d ppm 8.16–8.19 (d, 1H, ar–H), 8.09–
8.11 (d, 1H, ar–H), 8.03–8.05 (d, 1H, ar–H), 7.92–7.95 (d,
1H, ar–H), 7.85–7.87 (d, 1H, ar–H), 7.81–7.83 (d, 1H, ar–H),
7.74–7.76 (d, 1H, ar–H), 7.68–7.69 (m, 3H, ar–H), 7.60–7.63
(m, 3H, ar–H), 7.55–7.57 (m, 3H, ar–H), 7.53 (1H, s, ar–H),
7.47 (1H, s, ar–H), 5.71 (s, 1H, –CH=N), 5.68 (s, 1H,
–CH=N–), 5.63 (s, 1H, –CH=N–), 5.59 (s, 1H, –CH=N–).
13C NMR (DMF–d6) d ppm 143.05–149.11 (12C, ar–C),
138.78–141.12 (12C, ar–C), 132.06–136.27 (6C, ar–C),
127.99–130.67 (8C, thiadiazole carbons). Anal. Found (calc.)
for C42H22N16O8S4 (%): C, 50.08 (50.09); H, 2.21 (2.20); N,
22.27 (22.26), S, 12.73 (12.74).
2.2.2.6. 1,2,4,5-Tetra[5-(4-bromobenzylideneamino)-1,3,4-thia-
diazole-2-yl]benzene 8. (Yield: 85%). mp 287–288 C; IR
(KBr) cm1 3065 (m C–H), 1613 (m C=N), 1564 (m C=C).
1H
NMR (DMF–d6) d ppm 8.11–8.14 (d, 1H, ar–H), 8.04–8.07
(d, 1H, ar–H), 7.89–7.92 (d, 1H, ar–H), 7.83–7.85 (d, 1H,
ar–H), 7.78–7.80 (d, 1H, a–H), 7.72–7.74 (d, 1H, ar–H),
7.66–7.69 (d, 1H, ar–H), 7.60–7.63 (m, 3H, ar–H), 7.56–7.58
(m, 3H, ar–H), 6.52–7.54 (m, 3H, ar–H), 7.50 (1H, s, ar–H),
7.46 (1H, s, ar–H), 5.74 (s, 1H, –CH=N), 5.66 (s, 1H, –
CH=N–), 5.63 (s, 1H, –CH=N–), 5.54 (s, 1H, –CH=N–).
13C NMR (DMF–d6) d ppm 142.21–147.34 (12C, ar–C),
137.08–140.24 (12C, ar–C), 131.56–134.74 (6C, ar–C),
124.91–128.57 (8C, thiadiazole carbons). Anal. Found (calc.)
for C42H22Br4N12S4 (%): C, 44.14 (44.15); H, 1.95 (1.94); N,
14.70 (14.71), S, 11.22 (11.23).
2.2.2.7. 1,2,4,5-Tetra[5-(4-methoxybenzylideneamino)-1,3,4-
thiadiazole-2-yl]benzene 9. (Yield: 68%). mp > 360 C; IR
(KBr) cm1 3045 (m C–H), 2967 (m C–H aliphatic), 1615 (m C=N),
1536 (m C=C).
1H NMR (DMF–d6) d ppm 8.09–8.11 (d, 1H,
ar–H), 8.02–8.04 (d, 1H, ar–H), 7.94–7.96 (d, 1H, ar–H),
7.85–7.87 (d, 1H, ar–H), 7.81–7.83 (d, 1H, ar–H), 7.77–7.79
(d, 1H, ar–H), 7.70–7.72 (d, 1H, ar–H), 7.62–7.64 (m, 3H,
ar–H), 7.58–7.61 (m, 3H, ar–H), 7.53 (1H, s, ar–H), 7.48
(1H, s, ar–H), 6.56–6.59 (m, 3H, ar–H), 5.71 (s, 1H, –CH‚N),
5.69 (s, 1H, –CH‚N–), 5.63 (s, 1H, –CH‚N–), 5.59 (s, 1H, –
CH‚N–). 13C NMR (DMF–d6) d ppm 144.35–149.67 (12C,
ar–C), 136.13–140.97 (12C, ar–C), 130.79–134.69 (6C, ar–C),125.57–129.86 (8C, thiadiazole carbons). Anal. Found (calc.)
for C46H34N12O4S4 (%): C, 58.33 (58.34); H, 3.61 (3.62); N,
17.74 (17.75), S, 13.55 (13.54).
2.2.2.8. 1,2,4,5-Tetra[5-(4-chlorobenzylideneamino)-1,3,4-thia-
diazole-2-yl]benzene 10. (Yield: 75%). mp 243–244 C; IR
(KBr) cm1 3063 (m C–H), 1613 (m C=N), 1542 (m C=C).
1H NMR (DMF–d6) d ppm 8.10–8.14 (d, 1H, ar–H), 8.07–
8.11 (d, 1H, ar–H), 7.93–7.96 (d, 1H, ar–H), 7.88–7.90 (d,
1H, ar–H), 7.83–7.85 (d, 1H, ar–H), 7.75–7.77 (d, 1H, ar–H),
7.70–7.72 (d, 1H, ar–H), 7.63–7.65 (m, 3H, ar–H), 7.56–7.58
(m, 3H, ar–H), 6.48–7.51 (m, 3H, ar–H), 7.49 (1H, s, ar–H),
7.46 (1H, s, ar–H), 5.72 (s, 1H, –CH‚N), 5.70 (s, 1H, –
CH‚N–), 5.62 (s, 1H, –CH‚N–), 5.60 (s, 1H, –CH‚N–).
13C NMR (DMF–d6) d ppm 145.12–150.03 (12C, ar–C),
135.01–139.94 (12C, ar–C), 129.78–132.48 (6C, ar–C),
126.47–130.11 (8C, thiadiazole carbons). Anal. Found (calc.)
for C42H22Cl4N12S4 (%): C, 52.30 (52.29); H, 2.31 (2.30); N,
17.41 (17.42), S, 13.30 (13.29).
2.3. Biology investigation
2.3.1. Antimicrobial screening
The antibacterial activity of the synthesized compounds was
tested against four Gram-positive bacteria (S. aureus ATCC-
9144, S. epidermidis ATCC-155, M. luteus ATCC-4698 and
B. cereus ATCC-11778) and three Gram-negative bacteria
(E. coli ATCC-25922 and P. aeruginosa ATCC-2853) using
nutrient agar medium. The antifungal activities of the com-
pounds were tested against fungi and molds namely A. niger
ATCC-9029 and A. fumigatus ATCC-46645 using sabouraud
dextrose agar medium.
274 E. Yousif et al.2.3.2. Paper disc diffusion technique
The sterilized (Gillespie, 1994) (autoclaved at 120 C for
30 min) medium (40–50 C) was inoculated (1 mL/100 mL of
medium) with the suspension (105 cfu mL1) of the microor-
ganism (matched to McFarland barium sulfate standard) and
poured into a petridish to give a depth of 3–4 mm. The paper
was impregnated with the test compounds. The paper impreg-
nated with the test compounds (lg mL1 in dimethyl formam-
ide) was placed on the solidiﬁed medium. The plates were pre-
incubated for 1 h at room temperature and incubated at 37 C
for 24 and 48 h for antibacterial and antifungal activities,
respectively. Ciproﬂoxacin (100 lg/disc) and Ketoconazole
(100 lg/disc) were used as standard for antibacterial and anti-
fungal activities, respectively. The observed zone of inhibition
is presented in Table 1.
2.3.3. Minimum inhibitory concentration (MIC)
MIC (Hawkey and Lewis, 1994) of the synthesized compounds
was determined by agar streak dilution method. A stock solu-
tion of the synthesized compound (100 lg mL1) in dimethyl
formamide was prepared and graded quantities of the test
compounds were incorporated in a speciﬁed quantity of mol-
ten sterile agar (nutrient agar for antibacterial activity and sab-
ouraud dextrose agar medium for antifungal activity). A
speciﬁed quantity of the medium (40–50 C) containing the
compound was poured into a petridish to give a depth of 3–
4 mm and allowed to solidify. Suspension of the microorgan-
ism was prepared to contain approximately 105 cfu mL1
and applied to plates with serially diluted compounds in di-
methyl formamide to be tested and incubated at 37 C for 24
and 48 h for bacteria and fungi, respectively. The MIC was
considered to be the lowest concentration of the test substance
exhibiting no visible growth of bacteria or fungi on the plate.
The observed MIC is presented in Table 1.
3. Results and discussion
3.1. Synthesis
The synthesis involves reaction of pyromellitic acid 1 with thi-
osemicarbazide, using phosphorusoxy chloride for dehydrative
cyclization to produce 1,2,4,5-tetra (5-amino-1,3,4-thiadiazole-
2-yl)benzene 2. The Schiff bases under investigation were syn-
thesized in the usual way for the preparation of anils (Gaber
et al., 2001) by condensation of 1,2,4,5-tetra (5-amino-1,3,4-
thiadiazole-2-yl)benzene 2 with different aromatic aldehydes
in 1:4 molar proportion using absolute ethanol as solvent.
The reaction mixture was heated under reﬂux for about 24 h,
then ﬁltered off and washed with ethanol. The compounds
were puriﬁed by repeated recrystallization from ethanol and
then dried under vacuum. The synthetic scheme illustrates
the way used for the synthesis of target compounds (Scheme 1).
The structures of the compounds were characterized by IR, 1H
NMR, 13C NMR and elemental analysis.
3.2. Antimicrobial evaluation
Microorganisms have existed on the earth for more than 3.8
billion years and exhibit the greatest genetic and metabolic
diversities. They are an essential component of the biosphereand serve an important role in the maintenance and sustain-
ability of ecosystems. It is believed that they compose about
50% of the living biomass. In order to survive, they have
evolved mechanisms that enable them to respond to selective
pressure exerted by various environments and competitive
challenges. The disease-causing microorganisms have particu-
larly been vulnerable to man’s selﬁshness for survival who
has sought to deprive them of their habitat using antimicrobial
agents. These microorganisms have responded by developing
resistance mechanisms to ﬁght off this offensive. Currently
antimicrobial resistance among bacteria, viruses, parasites,
and other disease-causing organisms is a serious threat to
infectious disease management globally (Dun, 1999).
In order to appreciate the mechanisms of resistance, it is
important to understand how antimicrobial agents act. Anti-
microbial agents act selectively on vital microbial functions
with minimal effects or without affecting host functions. Dif-
ferent antimicrobial agents act in different ways. The under-
standing of these mechanisms as well as the chemical nature
of the antimicrobial agents is crucial in the understanding of
the ways how resistance against them develops. However, the
mechanism of action of antimicrobial agents can be catego-
rized further based on the structure of the bacteria or the func-
tion that is affected by the agents. These include generally the
following:
 Inhibition of the cell wall synthesis
 Inhibition of ribosome function
 Inhibition of nucleic acid synthesis
 Inhibition of folate metabolism
 Inhibition of cell membrane function
Microorganisms were increasingly becoming resistant to
ensure their survival against the arsenal of antimicrobial agents
to which they were being bombarded. They achieved this
through different means but primarily based on the chemical
structure of the antimicrobial agent and the mechanisms
through which the agents acted. The resistance mechanisms,
therefore, depend on which speciﬁc pathways are inhibited
by the drugs and the alternative ways available for those path-
ways that the organisms can modify to get a way around in or-
der to survive (Yeaman and Yount, 2003; Tenover, 2006).
Resistance can be described in two ways:
a) intrinsic or natural whereby microorganisms naturally
do not posses target sites for the drugs and, therefore,
the drug does not affect them or they naturally have
low permeability to those agents because of the differ-
ences in the chemical nature of the drug and the micro-
bial membrane structures especially for those that
require entry into the microbial cell in order to effect
their action or
b) acquired resistance whereby a naturally susceptible
microorganism acquires ways of not being affected by
the drug.
Acquired resistance mechanisms can occur through various
ways, Fig. 1.
For this reason all the synthesized compounds were evalu-
ated for in vitro antimicrobial activities against S. aureus
(ATCC-9144), S. epidermidis (ATCC-155), M. luteus (ATCC-
4698), B. cereus (ATCC-11778), E. coli (ATCC-25922),
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negative bacteria. They were also evaluated for their in vitro
antifungal potential against A. niger (ATCC-9029) as example
of fungi and A. fumigatus (ATCC-46645) as example of molds.
All the fungal and mold strains were clinical isolates, identiﬁed
with conventional morphological and biochemical methods.
From the results we can see that the synthesized com-
pounds were moderately active against tested microorganisms
with the range of MIC values for S. aureus (3.4–29.4 lg/mL),
S. epidermidis (2.1–28.2 lg/mL), M. luteus (1.2–28.7 lg/mL),
B. cereus (2.0–27.7 lg/mL), E. coli (3.1–32.8 lg/mL), P. aeru-
ginosa (2.4–36.2 lg/mL), A. niger (1.1–34.2 lg/mL) and A.
fumigatus (1.7–31.8 lg/mL) and the compound 1,2,4,5-tet-
ra[5-(4-nitrobenzylideneamino)-1,3,4-thiadiazole-2-yl]benzene
7 was found to exhibit the most potent antimicrobial activity
with the MICs of 3.4, 2.1, 1.2, 2.0, 3.1, 2.4, 1.1and 1.7 lg/
mL against S. aureus, S. epidermidis, M. luteus, B. cereus,
E. coli, P. aeruginosa, A. niger and A. fumigatus, respectively.
From SAR studies it is clear that compound 7 exhibited signif-
icant antimicrobial activity when compared to standard drugs
Ciproﬂoxin and Ketoconazole. Other compounds 1–6, 8–10
showed good antibacterial and antifungal activities. The most
potent antibacterial and antifungal activities exhibited by com-
pound 7 might be due to the presence of strong electron with-
drawing substituent two nitro groups on the benzylideneamino
moiety of the 1,3,4-thiadiazole. While other compounds,
though they contain weak electron withdrawing groups like
bromo, chloro and electron donating groups like methoxy,
methyl, hydroxy groups unfortunately produced weak antimi-
crobial activity (Table 1).
4. Conclusion
The antimicrobial activity of the synthesized compounds may
be due to the presence of the versatile pharmacophore which
might increase the lipophilic character of the molecules, which
facilitate the crossing through the biological membrane of the
microorganism and thereby inhibit their growth. For this rea-
son, we can see that compound 1,2,4,5-tetra[5-(4-nitrobenzy-
lideneamino)-1,3,4-thiadiazole-2-yl]benzene 7 was found to
exhibit the most potent antimicrobial activity against S. aureus
ATCC-9144, S. epidermidis ATCC-155,M. luteus ATCC-4698,
B. cereus ATCC-11778, E. coli ATCC-25922, P. aeruginosa
ATCC-2853, A. niger ATCC-9029 and A. fumigatus ATCC-
46645 when compared with Ciproﬂoxin and Ketoconazole.
In conclusion, we reported here a simple and convenient route
for the synthesis of some new derivatives based on 1,3,4-thia-
diazole for antimicrobial evaluation.Acknowledgments
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